ArticleClinical cancer research : an official journal of the American Association for Cancer Research2010

Mesalazine reduces mutations in transforming growth factor beta receptor II and activin type II receptor by improvement of replication fidelity in mononucleotide repeats.

Christoph Campregher et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.